



ELSEVIER

Reactions of some 2- and 4-*O*-triflylglycopyranosides with MeLi, *t*-BuOK, and pyridine

Ahmed El Nemr, Tsutomu Tsuchiya*

Institute of Bioorganic Chemistry, 3-34-17 Ida, Nakahara-ku, Kawasaki 211-0035, Japan

Received 13 October 2000; accepted 20 October 2000

Abstract

As an extension of our previous work on secondary triflates of carbohydrates [El Nemr, A.; Tsuchiya, T. *Tetrahedron Lett.* **1995**, *36*, 7665–7668. El Nemr, A.; Tsuchiya, T.; Kobayashi, Y. *Carbohydr. Res.* **1996**, *293*, 31–59. El Nemr, A.; Tsuchiya, T. *Carbohydr. Res.* **1997**, *301*, 77–87. El Nemr, A.; Tsuchiya, T. *Carbohydr. Res.* **1997**, *303*, 267–281], the reaction modes of several methyl 2- and 4-*O*-triflyl-*D*-glycopyranosides with MeLi (strong base), *t*-BuOK (moderately strong base), and pyridine (weak base) have been studied. This paper describes the reactions of 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-triflyl-*D*-gluco and -mannopyranosides with MeLi to give mainly the corresponding 2-*C*-methyl derivatives through α -elimination, with *t*-BuOK to give either the 2,3-unsaturated compounds through β -elimination or detriflyl 2-ols, and with hot pyridine to give the corresponding 2-pyridinium salts with inversion (except for the 2-*O*-triflyl- α -*D*-mannopyranoside (**8**)). 2,3,6-Tri-*O*-benzyl-4-*O*-triflyl- α -*D*-gluco and -mannopyranosides were also examined similarly. © 2001 Elsevier Science Ltd. All rights reserved.

Keywords: Triflate; MeLi; *t*-BuOK; Pyridine; Deuterated compound; α -Elimination; β -Elimination; Pyridinium salt; Nucleophilic substitution

We have recently reported^{1–3} a new reaction with some carbohydrate triflates when they are treated with MeLi or BuLi in diethyl ether giving *C*-methyl (or butyl) or unsaturated compounds, both through α -elimination with removal of a hydrogen (or deuterium) atom at the carbon bearing a CF₃SO₃ group as a proton (deuteron). To clarify the reaction modes for these compounds when the strongly basic Me(Bu)Li is changed to a weaker base such as *t*-BuOK or pyridine, 3-*O*-triflyl-*D*-gluco- and -*D*-allo-furanoses and the corresponding pyranosides were examined. It was found that, when *t*-BuOK was used, the 3-*O*-

triflyl-*D*-glucopyranosides afforded the corresponding 2,3- and/or 3,4-unsaturated compounds through α -elimination, and the 3-*O*-triflyl-*D*-allopyranosides gave the corresponding unsaturated compounds through β -elimination.⁴ When pyridine was used, however, most of the compounds readily gave the corresponding 3-pyridinium derivatives with inversion;⁴ it should be emphasized that methyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-*O*-triflyl- α -*D*-glucopyranoside readily gave the corresponding 3-deoxy-3-pyridinium-*D*-allopyranoside, even though the steric and electrostatic 1,3-diaxial interactions⁵ between MeO-1 and the pyridine molecule approaching C-3 would be expected, in the transition state, to hinder the reaction. The reaction should thus be facilitated by pyridine, a noncharged,^{5,6} which may generate only weak electrostatic

* Corresponding author.

E-mail address: seiyouken@mx1.alpha-web.ne.jp (T. Tsuchiya).

repulsion between its slightly negative-charged nitrogen and MeO-1. This paper is an extension of our previous work and describes the reactions of 2- and 4-*O*-triflyl-D-glycopyranosides with MeLi, *t*-BuOK, and pyridine to clarify the limitation of the foregoing reactions.

Synthesis of triflates

Methyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-triflyl-β-D-(2-²H)mannopyranoside (**10'**)[†] was prepared by the usual Swern oxidation–(NaBD₄) reduction procedure for methyl 3-*O*-benzyl-4,6-*O*-benzylidene-β-D-glucopyranoside (**5**),⁷ followed by triflation (**5** → **2** → **9'** → **10'**; **2** was prepared in high yield through a different route already reported⁸). Likewise, the 2-deuterated 2-*O*-triflyl-α-D anomer (**8'**) of **10'** was prepared from methyl 3-*O*-benzyl-4,6-*O*-benzylidene-α-D-glucopyranoside (**3**)⁷ via a similar route involving oxidation–(NaBD₄) reduction reactions (**3** → **1** → **3'**), with triflation of the resulting HO-2 group (to give **4'**), inversion of the C-2 function (with NaOBz–DMF), subsequent debenzoylation (to give **7'**), and triflation of the epi-HO-2 group.

Reactions of undeuterated and deuterated 2- and 4-triflates with MeLi, *t*-BuOK, and pyridine

At first, unlabeled methyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-triflyl-α- (**4**)^{9–11} and -β-D-glucopyranosides (**6**)⁹ were treated with *t*-BuOK in diethyl ether, whereupon only the detriflyl 3-ols **3**⁷ and **5**⁷ were produced, in 76 and 68% yields, respectively (this suggests that the process can be used for detriflation in some cases). As previously reported, compounds **4** and **6** are known to give the C-2-alkyl derivatives when treated with the strongly basic Me(Bu)Li in diethyl ether^{1,2} (Table 1). Compounds **4** and **6** were next treated with hot pyridine (~80 °C, 7 h). In this case, the 2-deoxy-2-pyridinium compounds having the

D-manno structure (**13** and **17**, respectively) were produced as the sole products in high yields (Table 1). This means that the S_N2 reactions by pyridine proceed as smoothly as those by such anionic nucleophiles as N₃[−] and F[−] or by the strongly basic hydrazine.^{6,9,12}

The D-mannopyranosides were examined next. When the 2-*O*-triflyl-α-D-mannopyranoside (**8**) was treated with MeLi, the C-2-methyl-D-gluco derivative (**12**)² was obtained in high yield unaccompanied by the D-manno isomer, along with the detriflyl 2-ol (**7**)¹³ and a trace amount of unsaturated compounds **11**.¹⁴ It is noteworthy that the abstraction of H-2 by Me(Bu)Li occurs readily, although, in **8**, the S_N2 reaction at C-2 is quite difficult.^{5,6,15} In the reactions of **8** and the corresponding D-2-derivative (**8'**) with *t*-BuOK, the 2,3-unsaturated compounds, **11** and **11'**, respectively, were mainly produced as observed for **4**, **6**, and **10'**, through β-(H-3) [but not α-(H- or D-2)] elimination, as indicated by the retention of deuterium at C-2 in **11'**.

Compound **8** was next heated in pyridine. In this case, no pyridinium compound was produced and three 2,3-unsaturated products [**11**, **18**, and **19**¹⁶ (major)] were formed. Compound **18** was assigned to be an α,β-unsaturated aldehyde based on the ¹H NMR (CHO, δ 9.98, *J*_{1,2} 7 Hz), ¹³C NMR (CHO, δ 190.5), and mass spectra. Compound **19** was assigned to be the 2-eno-1,5-lactone¹⁶ having possibly an *E*₅ conformation based on the ¹H NMR (H-2, δ 5.46; H-3, δ 7.30) and mass spectra. As observed in many other 2-sulfonylated α-D-mannopyranosides, the S_N2 reactions at C-2 occur with difficulty,^{5,6} possibly because of the steric repulsion between MeO-1 and the approaching nucleophiles to C-2 from the lower side in their transition states; in this case, however, electrostatic repulsion between MeO-1 and pyridine will be negligible, and the steric interaction should be the sole cause. Even so, the weakly basic, noncharged pyridine molecule can not attack at C-2 of **8** and instead attacks H-3 (to produce **11** by β-elimination) or H-1 (to produce **19** by β-elimination), as shown in Scheme 1. Compound **18** may be produced by hydrolysis of **11** with contaminant water in the pyridine, catalyzed by the CF₃SO₃H liberated during the reaction.


[†] Compounds with a primed number are for the deuterated derivatives of the corresponding nondeuterated compounds throughout this paper.

Next, the 2-labeled 2-*O*-triflyl- β -D-mannopyranoside (**10'**) was examined. Treatment of **10'** with MeLi (this reaction is not reported in Refs. 1–4) gave a mixture of four compounds: **14**,¹⁵ **14'**, **15**,² and **16**,² the ratio of the non-labeled (**14**) and 2-labeled 2,3-unsaturated compounds (**14'**) being 3:2 (20% in total). Compound **14** was considered to be produced by initial D-2 abstraction by MeLi (α -elimination) followed by 3 \rightarrow 2 proton migration with subsequent removal of the 2-OTf group^{1,2} (the whole reaction pattern closely resembles β -elimination and is liable to be so misjudged, in the absence of D-2 labeling). The 2-*C*-methyl-D-glucopyranoside (**15**) and -D-manno (**16**) derivatives (2:3, 76% in total) were considered to be produced by initial D-2 abstraction (α -elimination) followed by formation of the 2-oxo intermediate (by removal of the F₃CSO₂⁻ group) and rapid reaction of the intermediate with excess MeLi.^{1,2} The difference in the ratio of product-species between **8** and **10'** may be ascribed to the difference in anomeric configuration.

Compound **10'** was next treated with *t*-BuOK, whereupon a 2-labeled compound **14'** was exclusively produced by β -elimination; its ¹H NMR spectrum showed a very clear pattern, due to the absence of H-2, as compared with that obtained from the treatment of **10'** with MeLi (to give a mixture of **14** and **14'**; see Section 2). When **10'** was heated in pyridine, the 2-deoxy-2-pyridinium compound **20'** with the D-glucopyranoside structure was produced with inversion, in high yield and unaccompanied by any unsaturated or ring-contracted product¹⁷ (Table 1).

The 4-deuterated 4-*O*-triflyl- α -D-glucopyranosides (**21**³) and -galactopyranosides (**25**²) were next examined. As shown in Table 1, reactions of **21**³ and **25**² with MeLi or *t*-BuOK gave the corresponding 3,4- (**26'**) and/or 4,5-unsaturated (**22**,² **22'**) compounds, or the detriflyl 4-ol (**23**²), respectively; the reaction pattern (α - or β -elimination) and the product-species are fundamentally similar to that for the 3-*O*-triflyl- α -D-glycopyranosides already reported^{1,2} (see Table 1). When **21** and **25** were treated with hot pyridine, the corresponding 4-deoxy-4-pyridinium compounds, **24** and **27**,² respectively were produced readily under inversion in high yields.


Summarizing all our data for the secondary triflates hitherto studied [Refs. 1–4 with this paper], it is concluded that, in treatment with Me(Bu)Li in diethyl ether, all 2-*O*-triflyl-glycopyranosides tested gave the 2-*C*-methyl (or butyl) derivatives, mainly through α -elimination, and the 3-^{1,2} and 4-*O*-triflyl analogs gave mainly the corresponding unsaturated compounds through α -elimination or the detriflyl alcohols. In the reactions with *t*-BuOK, all compounds gave mainly the corresponding unsaturated compounds through β -elimination or the detriflyl alcohols. The foregoing results are therefore contradictory to the generally accepted concept that double bonds formed by removal of a sulfonyloxy group always arise through β -elimination, and, instead, indicate that double bonds are formed through either α - or β -elimination, depending upon the structures of the starting materials and the reaction conditions. In the case of pyridine, all compounds, except 2-*O*-triflyl- α -D-mannopyranoside (**8**), gave the corresponding pyridinium salts in high yields with inversion.



- | | |
|-----|---|
| 1 | R, R' = =O, X = H, Y = OCH ₃ |
| 2 | R, R' = =O, X = OCH ₃ , Y = H |
| 3 | R = H, R' = OH, X = H, Y = OCH ₃ |
| 3' | R = D, R' = OH, X = H, Y = OCH ₃ |
| 4 | R = H, R' = OTf, X = H, Y = OCH ₃ |
| 4' | R = D, R' = OTf, X = H, Y = OCH ₃ |
| 5 | R = H, R' = OH, X = OCH ₃ , Y = H |
| 5' | R = D, R' = OH, X = OCH ₃ , Y = H |
| 6 | R = H, R' = OTf, X = OCH ₃ , Y = H |
| 7 | R = OH, R' = H, X = H, Y = OCH ₃ |
| 7' | R = OH, R' = D, X = H, Y = OCH ₃ |
| 8 | R = OTf, R' = H, X = H, Y = OCH ₃ |
| 8' | R = OTf, R' = D, X = H, Y = OCH ₃ |
| 9 | R = OH, R' = H, X = OCH ₃ , Y = H |
| 9' | R = OH, R' = D, X = OCH ₃ , Y = H |
| 10' | R = OTf, R' = D, X = OCH ₃ , Y = H |

1. Experimental

General methods.—Optical rotations were determined with a Perkin–Elmer 241 polarimeter. Mass spectra were measured by the fast-atom bombardment method with a JEOL



Scheme 1.

SX-102 spectrometer. NMR spectra (¹H at 250 or 500 MHz, ¹³C at 125.8 MHz, and ¹⁹F at 235.35 MHz) were recorded with Bruker AC-250P or AMX-500 spectrometers, using Me₄Si and CFCl₃ (for ¹⁹F) as the internal and external references, respectively. TLC was performed on Silica Gel 60 F₂₅₄ (E. Merck 5715 and 5717), and detected by charring with aq 50% H₂SO₄. Column chromatography was performed on Wakogel C-200.

Preparation of starting materials

Methyl 3-O-benzyl-4,6-O-benzylidene-β-D-(2-²H)glucopyranoside (5') and **methyl 3-O-benzyl-4,6-O-benzylidene-β-D-(2-²H)mannopyranoside (9')**. To a cold (−78 °C) solution of oxalyl chloride (0.94 mL, 10.7 mmol) in CH₂Cl₂ (20 mL) was added Me₂SO (1.52 mL, 21.5 mmol) and after 15 min, methyl 3-O-benzyl-4,6-O-benzylidene-β-D-glucopyranoside (5)⁷ (2.0 g, 5.37 mmol) in CH₂Cl₂ (15 mL) was added dropwise and the mixture was stirred for 30 min. After the addition of Et₃N (3 g), the mixture was warmed to rt and kept for 1 h. Water (20 mL) was added, and the organic layer separated was washed with water, dried (Na₂SO₄), and concentrated. The residue was recrystallized from MeOH to give 2 as needles (1.85 g), mp 179–180 °C (lit.⁸ no data reported), [α]_D²² −76° (c 1, CHCl₃) (lit.⁸ no data reported); *m/z* 371.22 (M⁺ + 1); Anal. Calcd for C₂₁H₂₂O₆: *m/z* 370.14 for M⁺; ¹H NMR (CDCl₃): δ 3.59 (s, 3 H, OCH₃), 3.75 (dt, 1 H, J_{4,5} ≈ J_{5,6} 10, J_{5,6'} 4.3 Hz, H-5), 3.85 (t, 1 H, J_{6,6'} 10 Hz, H-6), 3.94 (dd, 1 H, H-4), 4.23 (dd, 1 H, J_{1,3} ~ 1, J_{3,4} 9.5 Hz, H-3), 4.45 (dd, 1 H, H-6'), 4.76 (d, 1 H, H-1), 4.86 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.58 (s, 1 H, CHPh); ¹³C NMR (CDCl₃): δ 58.01, 66.49, 68.58, 73.31, 81.92, 82.09, 101.11, 101.58, 196.45 (C-2). To a solu-

tion of 2 (1.50 g) in MeOH (40 mL) was added NaBD₄ (0.22 g, 5.27 mmol) and the solution was kept for 2 h at rt. Excess CO₂ (dry ice) was added, the solution was concentrated, and the residue was chromatographed (1:1 hexane–EtOAc) to give, from the faster-moving fractions, compound 5' as needles (97 mg, 6% based on 5), mp 182–183 °C (unlabeled compound, lit.⁷ 184–185 °C); [α]_D²² −45° (c 0.5, CHCl₃), (unlabeled, lit.⁷ [α]_D −48° (CHCl₃)); *m/z* 374.27 (M⁺ + 1); Anal. Calcd for C₂₁H₂₃DO₆: *m/z* 373.16 for M⁺; ¹H NMR (CDCl₃): δ 2.45 (s, 1 H, OH), 3.46 (dt, 1 H, J_{4,5} ≈ J_{5,6} 10.5, J_{5,6'} 5.0 Hz, H-5), 3.57 (s, 3 H, OCH₃), 3.68 (dd, 1 H, H-4), 3.69 (d, 1 H, J_{3,4} 8.0 Hz, H-3), 3.80 (t, 1 H, H-6), 4.33 (s, 1 H, H-1), 4.36 (dd, 1 H, H-6'), 4.88 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.58 (s, 1 H, CHPh). From the slower-moving fractions compound 9' was obtained as needles (1.38 g, 85% based on 5), mp 116–118 °C (lit.⁸ no data reported); [α]_D²² −30° (c 0.5, CHCl₃), (lit.⁸ no data reported); *m/z* 374.24 (M⁺ + 1); Anal. Calcd for C₂₁H₂₃DO₆: *m/z* 373.16 for M⁺; ¹H NMR (CDCl₃): δ 2.55 (s, 1 H, OH), 3.35 (ddd, 1 H, J_{4,5} 9.5, J_{5,6} 10, J_{5,6'} 4.5 Hz, H-5), 3.56 (s, 3 H, OCH₃), 3.65 (d, 1 H, J_{3,4} 9.5 Hz, H-3), 3.89 (t, 1 H, H-6), 4.14 (t, 1 H, H-4), 4.34 (dd, 1 H, H-6'), 4.41 (s, 1 H, H-1), 4.81 (ABq, 2 H, J 12 Hz, CH₂Ph) 5.61 (s, 1 H, CHPh), no H-2 signal was observed.

Methyl 3-O-benzyl-4,6-O-benzylidene-α-D-(2-²H)glucopyranoside (3'). A solution of 3⁷ (1.5 g, 4.03 mmol) in CH₂Cl₂ (10 mL) was oxidized as described for 2 to give 1 as needles (1.42 g), mp 146–147 °C, [α]_D²² +11° (c 1, CHCl₃); *m/z* 369.10 (M⁺ − 1), 371.12 (M⁺ + 1); Anal. Calcd for C₂₁H₂₂O₆: *m/z* 370.16 for M⁺; ¹H NMR (CDCl₃): δ 3.47 (s, 3 H, OCH₃), 3.81 (t, 1 H, H-6), 3.87 (dd, 1 H, H-4), 4.19 (dt, 1 H, J_{4,5} ≈ J_{5,6} 10.5, J_{5,6'} 5.0 Hz, H-5), 4.38 (dd, 1 H, H-6'), 4.53 (d, 1 H, J_{3,4} 10.5 Hz, H-3), 4.75 (s, 1 H, H-1), 4.82 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.56 (s, 1 H, CHPh). A solution of 1 (1.2 g) in MeOH (30 mL) was treated with NaBD₄ as described for 9' to give 3' as needles (1.16 g, 91% based on 3), mp 186–188 °C (unlabeled compound, lit.⁷ 187–188 °C), [α]_D²² +76° (c 1, CHCl₃) (unlabeled, lit.⁷ [α]_D +78° (CHCl₃)); *m/z* 372.16 (M⁺ − 1), 374.19 (M⁺ + 1); Anal. Calcd for

$C_{21}H_{23}DO_6$: m/z 373.19 for M^+ ; 1H NMR ($CDCl_3$): δ 2.33 (s, 1 H, OH), 3.45 (s, 3 H, OCH_3), 3.64 (t, 1 H, H-6), 3.75 (t, 1 H, H-4), 3.82 (d, 1 H, $J_{3,4}$ 10 Hz, H-3), 3.84 (dt, 1 H, $J_{4,5} \approx J_{5,6} \sim 10$, $J_{5,6'}$ 4 Hz, H-5), 4.30 (dd, 1 H, H-6'), 4.80 (s, 1 H, H-1), 4.87 (ABq, 2 H, J 11.5 Hz, CH_2Ph), 5.57 (s, 1 H, $CHPh$); no H-2 signal was observed.

Methyl 3-O-benzyl-4,6-O-benzylidene-2-O-triflyl- α -D-(2- 2H)glucopyranoside (4). Prepared from **3'** (1.0 g, 2.68 mmol) as described in the general procedure for triflation to give **4'** as needles (1.21 g, 89%), mp 82–84 °C (unlabeled compound, lit.⁹ 83–85 °C), $[\alpha]_D^{22} + 34^\circ$ (c 1, $CHCl_3$) (unlabeled, lit.⁹ $[\alpha]_D + 35.7^\circ$ ($CHCl_3$)); m/z 504.14 (M^+

Table 1

Reagent	Starting material	Product and yield (%)		Reference		
	 4 ⁹⁻¹¹	 11 ¹⁴	 3 ⁷			
MeLi		0	0	 91 ^a	2	
BuLi		0	0	 77 ^a	2	
^t BuOK		0	76			
Pyridine		0	0	 13 ⁸⁰		
	 6 ⁹	 14 ¹⁵	 5 ⁷			
MeLi		0	0	 39 ^a	2	
				 52 ^a	2	
BuLi		0	0	 18 ^a		
				 59 ^a		
^t BuOK		0	68			
Pyridine		0	0	 88 ¹⁷		
	 8 (R=H)	 11 ¹⁴	 11' ^D	 12 ²	 7 ¹³	
MeLi	8 (R=H)	trace		 77 ^a	18	
^t BuOK	8	93			0	
^t BuOK	8' (R=D)	5 ^a	89 ^b			
Pyridine	8	8	 18	 19 ¹⁶	20	
					45	

Table 1 (Continued)

Reagent	Starting material	Product and yield (%)	Reference
	 10'	 14 ¹⁵ 14' 15 ² 16 ²	
MeLi		12 ^a 8 ^b 31 ^a 45 ^a	
^t BuOK		0 84 ^b	
Pyridine		0 0 20' 94	
	 21	 22 ² 22' 23 23' ²	
MeLi	21 (R=H) ¹⁸	0	80
MeLi	21' (R=D) ³	16 ^a	0 79 ²
^t BuOK	21'	2.5 ^a 11.5 ^b	81 ³
Pyridine	21		 24 82
	 25'	 22 [2] 22' 26 26'	
MeLi	25' (R=D) ²	36 ^a	0 0 0
MeLi ^c	25 (R=H) ¹⁹	45 ^a	0 0 54 ^b
^t BuOK	25'	0 34 ^b	
Pyridine ^c	25		 27 ² 98

^aα-elimination^bβ-elimination^cThe reaction was performed as described in the general procedure.

– 1), 506.16 ($M^+ + 1$); Anal. Calcd for $C_{22}H_{22}DF_3O_8S$: m/z 505.11 for M^+ ; 1H NMR ($CDCl_3$): δ 3.47 (s, 3 H, OCH_3), 3.69 (t, 1 H, H-4), 3.76 (t, 1 H, H-6), 3.88 (dt, 1 H, $J_{4,5}$ 9, $J_{5,6}$ 10, $J_{5,6'}$ 4.5 Hz, H-5), 4.12 (d, 1 H, $J_{3,4}$ 9 Hz, H-3), 4.31 (dd, 1 H, H-6'), 4.81 (ABq, 2 H, J 11.5 Hz, CH_2Ph), 4.96 (s, 1 H,

H-1), 5.56 (s, 1 H, $CHPh$); no H-2 signal was observed.

Methyl 3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (7). A mixture of methyl 3-O-benzyl-4,6-O-benzylidene-2-O-triflyl- α -D-glucopyranoside (**4**)^{9–11} (2.1 g, 4.17 mmol) and NaOBz (1.81 g, 12.6 mmol) in DMF (50 mL)

was heated at 80 °C for 8 h. Water (50 mL) was added and the mixture was extracted with CHCl₃ (70 mL × 3). The extracts combined were washed with water, dried (Na₂SO₄), and concentrated in vacuo to give the crude 2-*O*-Bz derivative of **7** as a syrup (1.98 g). A mixture of the syrup and NaOMe in MeOH was allowed to stand for 1 h. After excess CO₂ (dry ice) was added, the mixture was concentrated and the residue was chromatographed (1:1 hexane–EtOAc) to give **7** as a syrup (1.21 g, 78%), [α]_D²² + 50° (*c* 1, CHCl₃), (lit.¹³ [α]_D²⁵ + 51° (CHCl₃)); ¹H NMR (CDCl₃): δ 2.74 (s, 1 H, OH), 3.36 (s, 3 H, OCH₃), 3.75–3.93 (m, 3 H, H-4,5,6), 4.02 (m, 1 H, H-2), 4.08 (m, 1 H, H-3), 4.27 (dd, 1 H, H-6'), 4.74 (d, 1 H, *J*_{1,2} 1.5 Hz, H-1), 4.78 (ABq, 2 H, *J* 11.5 Hz, CH₂Ph), 5.61 (s, 1 H, CHPh).

Methyl 3-O-benzyl-4,6-O-benzylidene- α -D-(2-²H)mannopyranoside (7'). A mixture of **4'** (1.05 g, 2.08 mmol) and NaOBz (0.91 g, 6.32 mmol) in DMF (30 mL) was heated as described for **7** to give the crude 2-*O*-Bz derivative of **7'** as a syrup (1.12 g). Debenzoylation (cat. NaOMe in MeOH) followed by chromatography (1:1 hexane–EtOAc) gave **7'** as a syrup (582 mg, 75%), [α]_D²² + 49° (*c* 1, CHCl₃), (unlabeled compound, lit.¹³ [α]_D²⁵ + 51° (CHCl₃)); *m/z* 372.17 (M⁺ – 1), 374.19 (M⁺ + 1); Anal. Calcd for C₂₁H₂₃DO₆: *m/z* 373.19 for M⁺; ¹H NMR (CDCl₃): δ 2.74 (s, 1 H, OH), 3.36 (s, 3 H, OCH₃), 3.79 (dt, 1 H, *J*_{4,5} ≈ *J*_{5,6} ~ 10, *J*_{5,6'} 4 Hz, H-5), 3.86 (t, 1 H, H-6), 3.92 (t, 1 H, H-4), 4.08 (d, 1 H, *J*_{3,4} 10 Hz, H-3), 4.27 (dd, 1 H, H-6'), 4.74 (s, 1 H, H-1), 4.78 (ABq, 2 H, *J* 11.5 Hz, CH₂Ph), 5.61 (s, 1 H, CHPh).

General procedure for preparation of triflates.—To a cold (–10 °C) solution of an alcohol (1 mmol) in 2:1 CH₂Cl₂–pyridine (6 mL) was added (CF₃SO₂)₂O (1.3 mmol) and the solution was kept for 2 h at 0 °C. After addition of water (0.5 mL), the mixture was concentrated, and the residue was purified by chromatography (3:1 hexane–EtOAc).

Methyl 3-O-benzyl-4,6-O-benzylidene-2-O-triflyl- α -D-mannopyranoside (8). Prepared from **7**, needles (83%), mp 90–91 °C, [α]_D²² + 18° (*c* 1, CHCl₃); *m/z* 505.15 (M⁺ + 1);

Anal. Calcd for C₂₂H₂₃F₃O₈S: *m/z* 504.11 for M⁺; ¹H NMR (CDCl₃): δ 3.40 (s, 3 H, OCH₃), 3.82 (m, 1 H, H-5), 3.87 (t, 1 H, H-6), 4.03 (m, 2 H, H-3,4), 4.26 (dd, 1 H, H-6'), 4.78 (ABq, 2 H, *J* 12 Hz, CH₂Ph), 4.84 (d, 1 H, H-1), 5.08 (t, 1 H, *J*_{1,2} ≈ *J*_{2,3} ~ 1.5 Hz, H-2), 5.62 (s, 1 H, CHPh). Anal. Calcd for C₂₂H₂₃F₃O₈S: C, 52.38; H, 4.60. Found: C, 52.29; H, 4.59.

Methyl 3-O-benzyl-4,6-O-benzylidene-2-O-triflyl- α -D-(2-²H)mannopyranoside (8'). Prepared from **7'** as needles (81%), mp 91–93 °C (unlabeled compound, 90–91 °C), [α]_D²² + 18° (*c* 1, CHCl₃) (unlabeled, [α]_D²² + 18° (CHCl₃)); *m/z* 504.02 (M⁺ – 1), 506.02 (M⁺ + 1); Anal. Calcd for C₂₂H₂₂DF₃O₈S: *m/z* 505.11 for M⁺; ¹H NMR (CDCl₃): δ 3.39 (s, 3 H, CH₃), 3.81 (dt, 1 H, *J*_{4,5} ≈ *J*_{5,6} 10, *J*_{5,6'} 4 Hz, H-5), 3.85 (t, 1 H, H-6), 4.03 (m, 2 H, H-3,4), 4.26 (dd, 1 H, H-6'), 4.78 (ABq, 2 H, *J* 12 Hz, CH₂Ph), 4.84 (s, 1 H, H-1), 5.08 (br s, 0.06 H, H-2), 5.62 (s, 1 H, CHPh).

Methyl 3-O-benzyl-4,6-O-benzylidene-2-O-triflyl- β -D-(2-²H)mannopyranoside (10'). Prepared from **9'** as needles (93%), mp 98–99 °C (unlabeled compound, lit.¹⁵ 99 °C), [α]_D²² – 35° (*c* 1, CHCl₃), (unlabeled, lit.¹⁵ [α]_D²² – 36° (CHCl₃)); *m/z* 506.23 (M⁺ + 1); Anal. Calcd for C₂₂H₂₂DF₃O₈S: *m/z* 505.11 for M⁺; ¹H NMR (CDCl₃): δ 3.37 (ddd, 1 H, *J*_{4,5} 9.5, *J*_{5,6} 10.3, *J*_{5,6'} 5 Hz, H-5), 3.55 (s, 3 H, OCH₃), 3.75 (d, 1 H, H-3), 3.90 (t, 1 H, H-6), 4.00 (t, 1 H, *J*_{3,4} ≈ *J*_{4,5} 9.5 Hz, H-4), 4.33 (dd, 1 H, H-6'), 4.51 (s, 1 H, H-1), 4.80 (ABq, 2 H, *J* 12 Hz, CH₂Ph), 5.62 (s, 1 H, CHPh).

General procedure for the reactions of triflates with MeLi.—To a cold (–50 °C) solution of a triflate (0.2 mmol) in dry Et₂O (5 mL) was added MeLi (0.8 mmol, as a 1.4 M solution in Et₂O), and the solution was kept for 1 h at rt. Aq 2 M NH₄Cl (5 mL) and CHCl₃ (50 mL) were stirred in and the organic layer separated was washed with water, dried (Na₂SO₄), concentrated, and the residue was chromatographed.

Reaction of 8 with MeLi. After the general procedure followed by chromatography (1:1 hexane–EtOAc), **8** (100 mg) gave **12**² (59 mg) and **7**¹³ (13 mg) as syrups, respectively.

Reaction of 10' with MeLi. After the general procedure, **10'** (100 mg) gave, on chromatography (5:1 hexane–EtOAc), a 3:2 mixture of **14⁹** and **14'** as needles (14 mg, 20%), mp 82–84 °C (unlabeled compound, lit.¹⁵ 83 °C), $[\alpha]_{\text{D}}^{22} - 108^{\circ}$ (*c* 0.5, CHCl₃) (unlabeled, lit.¹⁵ $[\alpha]_{\text{D}} - 110^{\circ}$ (CHCl₃)); ¹H NMR (CDCl₃): δ 3.42 (s, 3 H, OCH₃), 3.81 (dt, 1 H, $J_{4,5}$ 8.5, $J_{5,6}$ 10, $J_{5,6'}$ 4 Hz, H-5), 3.91 (t, 1 H, H-6), 4.32 (dd, 1 H, H-6'), 4.44 (d with narrow multiplets, 1 H, H-4), 4.70 (t, 0.6 H, $J_{1,2} \approx J_{2,4} \sim 1.5$ Hz, H-2), 4.88 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.39 (dd, 0.6 H; d, 0.4 H, $J_{1,4} \sim 2.5$ Hz, H-1), 5.62 (s, 1 H, CHPh). Further development with 1:1 hexane–EtOAc gave, from the faster-moving fractions, compound **15** as a syrup (24 mg, 31%), $[\alpha]_{\text{D}}^{22} - 41^{\circ}$ (*c* 1, CHCl₃), (unlabeled, lit.² $[\alpha]_{\text{D}}^{24} - 43^{\circ}$ (CHCl₃)); ¹H NMR (CDCl₃): all signals are identical with those reported.² From the slower-moving fractions compound **16** was obtained as a solid (34 mg, 45%), $[\alpha]_{\text{D}}^{22} - 37^{\circ}$ (*c* 1, CHCl₃), (unlabeled, lit.² $[\alpha]_{\text{D}}^{24} - 35^{\circ}$ (CHCl₃)); ¹H NMR (CDCl₃): all signals are identical with those reported.²

General procedure for the reactions of triflates with t-BuOK.—To a solution of a triflate (0.2 mmol) in dry ether (3 mL) was added *t*-BuOK (0.6 mmol), and the mixture was stirred for 3 h at rt. Water (7 mL) was added and the resulting mixture was extracted with CHCl₃ (20 mL \times 3). The combined organic solution was washed with water, dried (Na₂SO₄), and concentrated. The residue was chromatographed on silica gel with 1:1 hexane–EtOAc.

Reaction of 8 with t-BuOK. After the general procedure, **11** was obtained as needles (93%), mp 121–122 °C (lit.¹⁴ 120–121 °C), $[\alpha]_{\text{D}}^{22} + 56^{\circ}$ (*c* 1, CHCl₃) (lit.¹⁴ $[\alpha]_{\text{D}}^{22} + 59^{\circ}$ (*c* 0.6, CHCl₃)); m/z 353.17 ($M^+ - 1$), 355.17 ($M^+ + 1$); Anal. Calcd for C₂₁H₂₂O₅: m/z 354.15 for M^+ ; ¹H NMR (CDCl₃): δ 3.41 (s, 3 H, OCH₃), 3.83 (t, 1 H, H-6), 4.11 (dt, 1 H, $J_{4,5} \approx J_{5,6}$ 10, $J_{5,6'}$ 4.5 Hz, H-5), 4.26 (dd, 1 H, H-4), 4.30 (dd, 1 H, H-6'), 4.74 (dd, 1 H, $J_{1,2}$ 3.2, $J_{2,4} \sim 1.6$ Hz, H-2), 4.86 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.01 (d, 1 H, H-1), 5.58 (s, 1 H, CHPh).

Reaction of 8' with t-BuOK to give methyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-(2-²H)erythro-hex-2-enopyranoside (11'). Needles,

mp 119–121 °C (unlabeled compound, lit.¹⁴ 120–121 °C), $[\alpha]_{\text{D}}^{22} + 57^{\circ}$ (*c* 1, CHCl₃) (unlabeled, lit.¹⁴ $[\alpha]_{\text{D}} + 59^{\circ}$ (*c* 0.6, CHCl₃)); m/z 354.13 ($M^+ - 1$), 356.13 ($M^+ + 1$); Anal. Calcd for C₂₁H₂₁DO₅: m/z 355.15 for M^+ ; ¹H NMR (CDCl₃): δ 3.41 (s, 3 H, OCH₃), 3.83 (t, 1 H, H-6), 4.11 (dt, 1 H, $J_{4,5}$ 9, $J_{5,6}$ 10, $J_{5,6'}$ 4.5 Hz, H-5), 4.26 (dd, 1 H, $J_{1,4} \sim 1$ $J_{4,5}$ 9 Hz, H-4), 4.30 (dd, 1 H, H-6'), 4.74 (dd, 0.06 H, H-2), 4.87 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.02 (s, 1 H, H-1), 5.59 (s, 1 H, CHPh).

Reaction of 10' with t-BuOK. After the general procedure, **14'** was obtained as needles (84%), mp 83–84 °C (unlabeled compound, lit.¹⁵ 83 °C), $[\alpha]_{\text{D}}^{22} - 109^{\circ}$ (*c* 1, CHCl₃), (unlabeled, lit.¹⁵ $[\alpha]_{\text{D}} - 110^{\circ}$ (CHCl₃)); m/z 354.21 ($M^+ - 1$); Anal. Calcd for C₂₁H₂₁DO₅: m/z 355.15 for M^+ ; ¹H NMR (CDCl₃): δ 3.42 (s, 3 H, OCH₃), 3.81 (dt, 1 H, $J_{4,5}$ 8.5, $J_{5,6}$ 10, $J_{5,6'}$ 4 Hz, H-5), 3.90 (t, 1 H, H-6), 4.32 (dd, 1 H, H-6'), 4.44 (dd, 1 H, H-4), 4.70 (t, ~ 0.06 H, H-2), 4.88 (ABq, 2 H, J 12 Hz, CH₂Ph), 5.39 (d, 1 H, $J_{1,4}$ 2.5 Hz, H-1), 5.62 (s, 1 H, CHPh).

Reaction of 21¹³ with t-BuOK to give methyl 2,3,6-tri-O-benzyl-4-deoxy- β -L-threo-hex-4-enopyranoside (22²), methyl 2,3,6-tri-O-benzyl-4-deoxy- β -L-(4-²H)threo-hex-4-enopyranoside (22') and methyl 2,3,6-tri-O-benzyl- α -D-(4-²H)glucopyranoside (23²). Chromatography as described in the general procedure gave a 1:4.5 mixture of **22** and **22'** as a syrup (14%), $[\alpha]_{\text{D}}^{22} + 79^{\circ}$ (*c* 0.5, CHCl₃) (unlabeled compound, lit.² $[\alpha]_{\text{D}}^{22} + 78^{\circ}$ (*c* 1, CHCl₃)); ¹H NMR (CDCl₃): δ 3.49 (s, 3 H, OCH₃), 3.78 (dd, 1 H, $J_{1,2}$ 2.5, $J_{2,3}$ 7 Hz, H-2), 3.92 (sl. br s, 2 H, H-6,6'), 4.23 (\sim dt, 1 H, $J_{2,3}$ 7, $J_{3,6} \approx J_{3,6'} \sim 1$ Hz, H-3); 4.54, 4.63, and 4.77 (each ABq, 2 H, J 12 Hz, CH₂Ph \times 3), 4.85 (d, 1 H, H-1), 5.04 (d, 0.18 H, $J_{3,4}$ 3 Hz, H-4). Further development gave **23'** as a syrup (81%), $[\alpha]_{\text{D}}^{22} + 11.5^{\circ}$ (*c* 0.6, CHCl₃) (lit.² $[\alpha]_{\text{D}}^{22} + 12^{\circ}$ (CHCl₃)).

Reaction of 25² with t-BuOK to give methyl 2,3,6-tri-O-benzyl-4-deoxy- β -L-(4-²H)threo-hex-4-enopyranoside (22') and 2,3,6-tri-O-benzyl-4-deoxy- α -D-(4-²H)erythro-hex-3-enopyranoside (26'). Chromatography as described in the general procedure gave **22'** as a syrup (34%), $[\alpha]_{\text{D}}^{22} + 79^{\circ}$ (*c* 1.2, CHCl₃) (unlabeled compound, lit.² $[\alpha]_{\text{D}}^{22} + 78^{\circ}$ (*c* 1, CHCl₃);

^1H NMR (CDCl_3): δ 3.49 (s, 3 H, OCH_3), 3.78 (dd, 1 H, $J_{1,2}$ 2.5, $J_{2,3}$ 7 Hz, H-2), 3.92 (sl. br s, 2 H, H-6,6'), 4.23 (dt, 1 H, $J_{2,3}$ 7, $J_{3,6} \approx J_{3,6'} \sim 1$ Hz, H-3); 4.54, 4.63, and 4.77 (each ABq, 2 H, J 12 Hz, $\text{CH}_2\text{Ph} \times 3$), 4.85 (d, 1 H, H-1). Further development gave **26'** as a syrup (54%), $[\alpha]_{\text{D}}^{22} -40^\circ$ (c 1.1, CHCl_3); m/z 446.30 ($\text{M}^+ - 1$); Anal. Calcd for $\text{C}_{28}\text{H}_{29}\text{DO}_5$: m/z 447.22 for M^+ ; ^1H NMR (acetone- d_6): δ 3.45 (s, 3 H, OCH_3), 3.50 (dd, 1 H, H-6), 3.58 (dd, 1 H, H-6'), 4.16 (dd, 1 H, $J_{1,2}$ 4.0, $J_{2,5}$ 2.5 Hz, H-2), 4.40 (dt, 1 H, $J_{2,5}$ 2.5, $J_{5,6}$ 5.0, $J_{5,6'}$ 6.0 Hz, H-5), 4.58, 4.75 and 4.82 (each ABq, 2 H, J 12 Hz, $\text{CH}_2\text{Ph} \times 3$), 4.94 (d, 1 H, H-1).

General procedure for the reactions of triflates with pyridine.—A solution of a triflate (0.2 mmol) in pyridine (2 mL) was heated at 80°C for 7 h, except for **8**. After excess pyridine has been evaporated in vacuo, the residue dissolved in CHCl_3 (20 mL) was washed with water, dried (Na_2SO_4), and concentrated. The residue was chromatographed on silica gel (5:1 CHCl_3 –MeOH) to give the pyridinium trifluoromethanesulfonate.

*Reaction of **4**^{9–11} with pyridine to give methyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(pyridinium-1-yl)- α -D-mannopyranoside triflate (**13**).* Syrup, $[\alpha]_{\text{D}}^{22} -41^\circ$ (c 0.5, CHCl_3); ^1H NMR (CDCl_3): δ 3.45 (s, 3 H, OCH_3), 3.80 (t, 1 H, $J_{5,6} \approx J_{6,6'}$ 10 Hz, H-6), 4.06 (dt, 1 H, $J_{4,5} \approx J_{5,6}$ 10, $J_{5,6'}$ 5.5 Hz, H-5), 4.10 (t, 1 H, $J_{3,4}$ 10 Hz, H-4), 4.32 (dd, 1 H, H-3), 4.38 (dd, 1 H, H-6'), 4.78 (ABq, 2 H, J 12 Hz, CH_2Ph), 5.22 (d, 1 H, $J_{1,2} < 0.5$, $J_{2,3}$ 5.8 Hz, H-2), 5.39 (s, 1 H, H-1), 5.61 (s, 1 H, CHPh), 8.00, 8.40 and 8.97 (each m of 2, 1, and 2 H, respectively, $\text{C}_5\text{H}_5\text{N}$); ^{19}F NMR (CDCl_3): $\delta -78.54$ (s, CF_3SO_3).

*Reaction of **6**⁹ with pyridine to give methyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(pyridinium-1-yl)- β -D-mannopyranoside triflate (**17**).* Needles, mp 73 – 75°C , $[\alpha]_{\text{D}}^{23} +38^\circ$ (c 1, CHCl_3); m/z 434.16 (M^+); Anal. Calcd for $\text{C}_{26}\text{H}_{28}\text{NO}_5$: m/z 434.20 for M^+ ; ^1H NMR (CDCl_3): δ 1.70 (s, 2 H, H_2O), 3.50 (s, 3 H, OCH_3), 3.63 (dt, 1 H, $J_{5,6'}$ 5 Hz, H-5), 3.83 (t, 1 H, H-6), 4.01 (t, 1 H, $J_{3,4} \approx J_{4,5}$ 10 Hz, H-4), 4.38 (dd, 1 H, H-6'), 4.41 (dd, 1 H, H-3), 4.82 (ABq, 2 H, J 12 Hz, CH_2Ph), 5.16 (d, 1 H, H-1), 5.60 (s, 1 H, CHPh), 5.78 (dd,

1 H, $J_{1,2}$ 2.8, $J_{2,3}$ 5.5 Hz, H-2), 7.92, 8.31 and 9.06 (m of 2, 1, and 2 H, respectively, $\text{C}_5\text{H}_5\text{N}$). Anal. Calcd for $\text{C}_{27}\text{H}_{28}\text{F}_3\text{NO}_8\text{S}\cdot\text{H}_2\text{O}$: C, 53.90; H, 5.03; N, 2.33. Found: C, 54.03; H, 5.06; N, 2.38.

*Reaction of **8** with pyridine to give **11**¹⁴, 3-O-benzyl-4,6-O-benzylidene-2-deoxy-D-erythro-hex-2-enal (**18**), and 4,6-O-benzylidene-2,3-dideoxy-D-erythro-hex-2-eno-1,5-lactone (**19**)¹⁶.* Heating **8** (120 mg, 0.24 mmol) in pyridine (4 mL) at 60°C for 12 h followed by concentration of the solution in vacuo gave a residue, which was chromatographed (1:1 hexane–EtOAc) to give, from the faster-moving fractions, compound **11**¹⁴ as needles (7 mg, 8%) and, from the second-moving fractions, compound **19** as a solid (25 mg, 45%), mp 135 – 136°C (lit.¹⁶ 136 – 137°C), $[\alpha]_{\text{D}}^{22} +32^\circ$ (c 1, CHCl_3) (lit.¹⁶ $[\alpha]_{\text{D}}^{27} +33^\circ$ (c 1, CHCl_3)); m/z 233.15 ($\text{M}^+ + 1$); Anal. Calcd for $\text{C}_{13}\text{H}_{12}\text{O}_4$: m/z 332.09 for M^+ ; ^1H NMR (CDCl_3): δ 4.04 (unresolved m, 1 H, H-6; signals are complex due to virtual couplings involving H-4), 4.38–4.53 (unresolved m, 3 H, H-4,5,6'), 5.46 (d, 1 H, H-2), 5.60 (s, 1 H, CHPh), 7.30 (d, 1 H, H-3); $J_{2,3}$ 6 Hz; ^{13}C NMR (CDCl_3): δ 67.91 (C-6), 73.08 (C-4 or 5), 77.52 (C-5 or 4), 102.35 (CHPh); 106.32 (C-2), 126.45, 128.34, 129.47 and 136.23 (Ph), 161.36 (C-3), 188.07 (C-1), which were confirmed by the C–H correlation spectrum; the H-4,5, and 6' could not be resolved even in the spectrum in pyridine- d_5 . From the slowest-moving fractions compound **18** was obtained as a syrup (18 mg, 20%), $[\alpha]_{\text{D}}^{22} +0.2^\circ$ (c 1, CHCl_3); m/z 339.16 ($\text{M}^+ - 1$), 341.16 ($\text{M}^+ + 1$); Anal. Calcd for $\text{C}_{20}\text{H}_{20}\text{O}_5$: m/z 340.13 for M^+ ; ^1H NMR (CDCl_3): δ 2.61 (d, 1 H, OH), 3.73 (dd, 1 H, $J_{5,6}$ 10, $J_{6,6'}$ 11 Hz, H-6), 4.20 (m, 1 H, H-5), 4.40 (dd, 1 H, $J_{5,6'}$ 5.5 Hz, H-6'), 4.90 (d, 1 H, $J_{4,5}$ 9.2 Hz, H-4), 4.95 (ABq, 2 H, J 11.5 Hz, CH_2Ph), 5.59 (s, 1 H, CHPh), 5.66 (d, 1 H, $J_{1,2}$ 7 Hz, H-2), 9.98 (d, 1 H, H-1); ^{13}C NMR (CDCl_3): δ 63.33 (C-5), 71.28 (C-6), 71.38 (C-4), 79.66 (CH_2Ph), 101.81 (CHPh), 108.33 (C-2), 190.50 (C-1).

*Reaction of **10**' with pyridine to give methyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(pyridinium-1-yl)- β -D-(2-²H)glucopyranoside triflate (**20**').* Syrup, $[\alpha]_{\text{D}}^{23} +38^\circ$ (c 1, CHCl_3); m/z 435.42 (M^+); Anal. Calcd for $\text{C}_{26}\text{H}_{27}$

DNO₅: m/z 435.20 for M⁺; ¹H NMR (CDCl₃): δ 3.37 (s, 3 H, OCH₃), 3.83 (t, 1 H, $J_{5,6} \approx J_{6,6'}$ 10.2 Hz, H-6), 3.87 (dd, 1 H, $J_{3,4}$ 8.0, $J_{4,5}$ 9.5 Hz, H-4), 4.04 (dt, 1 H, H-5), 4.45 (dd, 1 H, $J_{5,6'}$ 4.5 Hz, H-6'), 4.57 (ABq, 2 H, J 12 Hz, CH₂Ph), 4.58 (d, 1 H, H-3), 5.36 (s, 1 H, H-1), 5.63 (s, 1 H, CHPh), 7.87, 8.34 and 8.83 (each m of 2, 1, and 2 H, respectively, C₅H₅N); ¹⁹F NMR (CDCl₃): δ -78.62 (s, CF₃SO₃).

Reaction of **21**¹⁸ with pyridine to give methyl 4-deoxy-2,3,6-tri-O-benzyl-4-(pyridinium-1-yl)- α -D-galactopyranoside triflate (**24**). Syrup, $[\alpha]_{\text{D}}^{22} + 48^\circ$ (c 2, CHCl₃), ¹H NMR (CDCl₃): δ 3.41 (s, 3 H, OCH₃), 3.58 (dd, 1 H, $J_{5,6}$ 5.5, $J_{6,6'}$ 10.5 Hz, H-6), 3.71 (dd, 1 H, $J_{1,2}$ 3.8, $J_{2,3}$ 10.5 Hz, H-2), 3.86 (dd, 1 H, $J_{5,6'}$ 4.5 Hz, H-6'), 4.21 (s, 2 H, CH₂Ph), 4.38 (dd, 1 H, H-3), 4.51 (dt, 1 H, H-5), 4.64 and 4.80 (each ABq, 2 H, CH₂Ph \times 2), 4.98 (d, 1 H, H-1), 5.55 (dd, 1 H, $J_{3,4}$ 5.5, $J_{4,5}$ 3.5 Hz, H-4); 7.70 (t, J 8.5 Hz, 2 H), 8.14 (m, 1 H) and 9.03 (d, 6 Hz, 2 H) (C₅H₅N).

Acknowledgements

We express deep thanks to Dr Hiroshi Naganawa of Institute of Microbial Chemistry, Ms Yoshiko Koyama and Ms Miwa Arai of our institute for measurements of mass spectra, NMR spectra, and assistance in preparing the manuscript, respectively. We are also grateful to Dr Yoshihiko Kobayashi for

preparation of some compounds and other valuable advice.

References

1. El Nemr, A.; Tsuchiya, T. *Tetrahedron Lett.* **1995**, *36*, 7665–7668.
2. El Nemr, A.; Tsuchiya, T.; Kobayashi, Y. *Carbohydr. Res.* **1996**, *293*, 31–59.
3. El Nemr, A.; Tsuchiya, T. *Carbohydr. Res.* **1997**, *301*, 77–87.
4. El Nemr, A.; Tsuchiya, T. *Carbohydr. Res.* **1997**, *303*, 267–281.
5. Richardson, A. C. *Carbohydr. Res.* **1969**, *10*, 395–402.
6. Miljkovic, M.; Gligorijevic, M.; Glisin, D. *J. Org. Chem.* **1974**, *39*, 3223–3226.
7. Garegg, P. J.; Iversen, T.; Oscarson, S. *Carbohydr. Res.* **1976**, *50*, C12–C14.
8. Daves Jr., G. D.; Kovác, P.; Glaudemans, C. P. J. *J. Carbohydr. Chem.* **1990**, *9*, 101–112.
9. Haradahira, T.; Maeda, M.; Omae, H.; Yano, Y.; Kojima, M. *Chem. Pharm. Bull.* **1984**, *32*, 4758–4766.
10. Baer, H. H.; Radatus, B. *Carbohydr. Res.* **1984**, *128*, 165–174.
11. Fleet, G. W. J.; Gough, M. J.; Shing, T. K. M. *Tetrahedron Lett.* **1984**, *25*, 4029–4032.
12. Ishido, Y.; Sakairi, N. *Carbohydr. Res.* **1981**, *97*, 151–155.
13. Nashed, M. A. *Carbohydr. Res.* **1978**, *60*, 200–205.
14. Kovác, P.; Yeh, H. J. C.; Jung, G. L.; Glaudemans, C. P. J. *J. Carbohydr. Chem.* **1986**, *5*, 497–512.
15. Haradahira, T.; Maeda, M.; Kai, Y.; Omae, H.; Kojima, M. *Chem. Pharm. Bull.* **1985**, *33*, 165–172.
16. Furuichi, B. K.; Yogai, S.; Miwa, T. *J. Chem. Soc. Chem. Commun.* **1980**, 66–68.
17. Tsuchiya, T.; Ajito, K.; Umezawa, S.; Ikeda, A. *Carbohydr. Res.* **1984**, *126*, 45–60.
18. Barrett, E.-P.; Goodman, L. *J. Org. Chem.* **1984**, *49*, 176–178.
19. Doboszewski, B.; Hay, G. W.; Szarek, W. A. *Can. J. Chem.* **1987**, *65*, 412–419.